Insulet Corporation revised revenue guidance for the fourth and full year ended December 31, 2014. For the quarter, the company expects revenue will be in the range of $71 to $73 million, versus prior estimates of $76 to $81 million a year ago. The company expects growth in the fourth quarter of 2014 of approximately 10% from its U.S. direct diabetes business and approximately 40% from its international diabetes business compared to the same period last year.

For the year, the company expects revenues to be in the range of $287 to $289 million, versus prior estimates of $292 to $297 million.

For the year 2015, the company expects that revenues associated with non-insulin drug delivery products will be in the range of $10 to $20 million.